地拉罗司减少了一位脑部铁蛋白沉积症患者脑内的含铁血黄素沉积。
Deferiprone reduces hemosiderin deposits in the brain of a patient with superficial siderosis.
机构信息
Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA.
出版信息
AJNR Am J Neuroradiol. 2011 Jan;32(1):E1-2. doi: 10.3174/ajnr.A2331. Epub 2010 Nov 4.
Abstract
A man with superficial siderosis showed improvement in symptoms and reduction in hemosiderin by MR imaging following treatment with deferiprone, a lipid-soluble iron chelator.
摘要
一名患有表面铁沉着症的男性患者，在接受脂溶性铁螯合剂地拉罗司治疗后，其症状改善，磁共振成像显示含铁血黄素减少。
相似文献
1
Deferiprone reduces hemosiderin deposits in the brain of a patient with superficial siderosis.
AJNR Am J Neuroradiol. 2011 Jan;32(1):E1-2. doi: 10.3174/ajnr.A2331. Epub 2010 Nov 4.
2
Pilot safety trial of deferiprone in 10 subjects with superficial siderosis.
Stroke. 2012 Jan;43(1):120-4. doi: 10.1161/STROKEAHA.111.628032. Epub 2011 Oct 27.
3
Agranulocytosis with deferiprone treatment of superficial siderosis.
BMJ Case Rep. 2013 Aug 7;2013:bcr2013010099. doi: 10.1136/bcr-2013-010099.
4
Treatment of superficial siderosis with iron chelation therapy.
BMJ Case Rep. 2013 Jul 9;2013:bcr2013009916. doi: 10.1136/bcr-2013-009916.
5
Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major.
Haematologica. 2011 Feb;96(2):e5-6; author reply e7-8. doi: 10.3324/haematol.2010.036061.
6
Treatment Response of Deferiprone in Infratentorial Superficial Siderosis: a Systematic Review.
Cerebellum. 2021 Jun;20(3):454-461. doi: 10.1007/s12311-020-01222-7. Epub 2021 Jan 6.
7
Quantitative clinical and radiological recovery in post-operative patients with superficial siderosis by an iron chelator.
J Neurol. 2022 May;269(5):2539-2548. doi: 10.1007/s00415-021-10844-8. Epub 2021 Oct 18.
8
CSF biomarkers in superficial siderosis: a new tool for diagnosis and evaluation of therapeutic efficacy of deferiprone--a case report.
Neurol Sci. 2014 Jul;35(7):1151-2. doi: 10.1007/s10072-014-1709-5. Epub 2014 Mar 14.
9
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.
Blood. 2006 May 1;107(9):3738-44. doi: 10.1182/blood-2005-07-2948. Epub 2005 Dec 13.
10
Two-year observational study of deferiprone in superficial siderosis.
CNS Neurosci Ther. 2018 Mar;24(3):187-192. doi: 10.1111/cns.12792. Epub 2017 Dec 28.
引用本文的文献
1
Iron dysregulation in mice engineered with a mutation associated with stuttering.
bioRxiv. 2025 Jul 31:2025.07.30.667752. doi: 10.1101/2025.07.30.667752.
2
Cochlear Implantation: A Treatment Approach of Hearing Loss in Superficial Siderosis.
J Int Adv Otol. 2025 May 20;21(3):1-5. doi: 10.5152/iao.2025.241682.
3
Treatment Response of Deferiprone in Infratentorial Superficial Siderosis: a Systematic Review.
Cerebellum. 2021 Jun;20(3):454-461. doi: 10.1007/s12311-020-01222-7. Epub 2021 Jan 6.
4
Outcomes of Cochlear Implantation in Patients with Superficial Siderosis: A Systematic Review and Narrative Synthesis.
J Int Adv Otol. 2020 Dec;16(3):443-455. doi: 10.5152/iao.2020.9037.
5
A Combination of Magnetic Resonance Imaging Techniques to Localize the Dural Defect in a Case of Superficial Siderosis-A Case Report.
Medicines (Basel). 2020 Jun 25;7(6):36. doi: 10.3390/medicines7060036.
6
Linking the low-density lipoprotein receptor-binding segment enables the therapeutic 5-YHEDA peptide to cross the blood-brain barrier and scavenge excess iron and radicals in the brain of senescent mice.
Alzheimers Dement (N Y). 2019 Nov 6;5:717-731. doi: 10.1016/j.trci.2019.07.013. eCollection 2019.
7
Ten years of iron chelation in a patient with superficial siderosis.
Neurol Sci. 2019 Sep;40(9):1947-1949. doi: 10.1007/s10072-019-03791-w. Epub 2019 Mar 4.
8
Two-year observational study of deferiprone in superficial siderosis.
CNS Neurosci Ther. 2018 Mar;24(3):187-192. doi: 10.1111/cns.12792. Epub 2017 Dec 28.
9
Auditory dysfunction in patients with cerebrovascular disease.
ScientificWorldJournal. 2014;2014:261824. doi: 10.1155/2014/261824. Epub 2014 Oct 23.
10
Normal cerebellar metabolism in a patient with superficial siderosis.
J Mov Disord. 2014 Oct;7(2):99-101. doi: 10.14802/jmd.14015. Epub 2014 Oct 30.
本文引用的文献
1
Neuroimaging in superficial siderosis: an in-depth look.
AJNR Am J Neuroradiol. 2010 Jan;31(1):5-14. doi: 10.3174/ajnr.A1628. Epub 2009 Sep 3.
2
Superficial siderosis: sealing the defect.
Neurology. 2009 Feb 17;72(7):671-3. doi: 10.1212/01.wnl.0000342457.22536.af.
3
Superficial siderosis: a case report and review of the literature.
Nat Clin Pract Neurol. 2007 Jan;3(1):54-8; quiz 59. doi: 10.1038/ncpneuro0356.
4
The pharmacokinetics and blood-brain barrier permeation of the chelators 1,2 dimethly-, 1,2 diethyl-, and 1-[ethan-1'ol]-2-methyl-3-hydroxypyridin-4-one in the rat.
Toxicology. 1996 Apr 30;108(3):191-9. doi: 10.1016/0300-483x(95)03301-u.
5
The pathogenesis of superficial siderosis of the central nervous system.
Ann Neurol. 1993 Nov;34(5):646-53. doi: 10.1002/ana.410340505.
6
Design, properties, and effective use of the oral chelator L1 and other alpha-ketohydroxypyridines in the treatment of transfusional iron overload in thalassemia.
Ann N Y Acad Sci. 1990;612:339-50. doi: 10.1111/j.1749-6632.1990.tb24321.x.
Zotero 插件